Our Journey
Headquartered in the USA with subsidiaries in India and Australia. We have discovered novel dual target acting microbial agents now in clinical trials.
Over the years, we have diversified our expertise in the areas of cancer biology and immunology.
Bugworks is developing novel class of broad-spectrum antibacterial agents and immunotherapies to treat patients with critical care needs in infection and cancer.
News & Announcements
Bugworks and GARDP join forces to accelerate development of a novel antibiotic to treat serious bacterial infections.
July 28, 2023 Published in GARDP
An engaging and informative podcast titled “What can we do to stop superbugs?” by Dr Anand Anandkumar, CEO with Alisha Wainwright onbehalf of Wellcome Trust.
June 28, 2023 Published in Wellcome Trust
Dr Santanu Datta and Vasan Sambandamurthy from Bugworks have contributed a chapter titled “Bugworks is a beacon of hope in the discovery of novel antibacterial agents” in the book “No Option: The Hidden Crisis and Hope for AMR“ presented by the AMR Declaration Trust.
June 22, 2023 Published in book by AMR DECLARATION TRUST
An article by Leela Maitreyi, Director, “Antimicrobial Resistance And Its Impact On Public Health”.
June 09, 2023 Published in Indiatimes
Our Story
